Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune checkpoint inhibitor combinations with axitinib in previously untreated advanced or metastatic renal cell carcinoma
2023-505816-39-00Phase 2Completed
- Sponsor
- Roche
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of axitinib in renal cell carcinoma (RCC) (2 arms), sponsored by Roche. Primary endpoint: Incidence and severity of adverse events. Started Apr 2023; status: completed.
02
Drugs
axitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2023-505816-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505816-39-00.